Globus Medical filings document formal disclosures for a medical device company focused on musculoskeletal solutions and enabling technologies. Recent Form 8-K reports furnish quarterly and annual operating results, preliminary sales information, financial guidance and related press releases covering net sales, earnings measures, cash flow and segment commentary.
The company’s proxy materials cover board elections, governance practices, executive compensation, equity awards and annual meeting matters. Other current reports document leadership transitions, director departures and related governance events, tying the filing record to Globus Medical’s operating performance, management structure and public-company reporting obligations.
Globus Medical, Inc. (GMED) insider filed a Form 144 notice to sell 7,500 shares of common stock. The planned sale, to be executed through Raymond James & Associates on the NYSE, has an stated aggregate market value of $675,000. The filing notes that 133,839,166 shares of common stock are outstanding. The shares to be sold were acquired on 11/25/2025 via a cashless stock option exercise from the issuer, with payment also dated 11/25/2025 and described as a cashless exercise.
Globus Medical Inc. (GMED) director reported an insider transaction involving company Class A common stock. On 11/12/2025, the reporting person exercised 25,000 stock options at an exercise price of $25.52 per share and on the same date sold 25,000 shares of Class A common stock at a weighted average price of $86.0002 per share. After these transactions, the director directly beneficially owns 516,275 shares of Class A common stock and indirectly beneficially owns 165,967 shares held in a family trust. The reported options were granted on January 25, 2016 and are fully vested.
Globus Medical (GMED) reported an insider transaction by a director. On 11/11/2025, the director exercised stock options for 25,000 Class A shares at $44.14 and then sold 25,000 Class A shares at a $84.2903 weighted average price.
Following these transactions, the director held 0 shares directly. The options were granted on May 1, 2019, were fully vested, and had an expiration date of 05/01/2029.
Globus Medical (GMED) reported a Form 144 notice for a proposed sale of up to 25,000 shares of common stock. The filing lists Raymond James & Associates as broker and indicates an aggregate market value of $2,148,750 for the shares. The approximate sale date is 11/12/2025, and the shares are listed on the NYSE.
The shares to be sold were acquired on 11/12/2025 via a cashless option exercise from the issuer, with payment described as Cashless Exercise. As context, shares outstanding were 133,839,166. This notice reflects a potential secondary sale by a holder under Rule 144.
Globus Medical (GMED): A stockholder filed a Form 144 notice to sell up to 25,000 shares of GMED common stock, reflecting an aggregate market value of $2,106,000. The planned broker is Raymond James & Associates, with sales listed for the NYSE and an approximate sale date of 11/11/2025.
The shares were acquired the same day via a cashless stock option exercise from the issuer for 25,000 shares, noted as a “Cashless Exercise.” The filing also lists 133,839,166 shares outstanding.
Globus Medical (GMED) filed a Form 144 indicating a proposed sale of 2,000 common shares through Raymond James & Associates, with an aggregate market value $170,000. The shares are listed on the NYSE, and the notice lists an approximate sale date of 11/10/2025.
The filer previously acquired 20,000 common shares via a stock option exercise on 09/13/2024 for cash. Recent activity by the same seller shows sales of 8,000 shares on 11/07/2025 for $647,681 and 10,000 shares on 09/15/2025 for $584,000. Shares outstanding were 133,839,166 at the time cited in the notice.
Globus Medical (GMED) reported a director’s open‑market sales of Class A common stock. On 11/07/2025, the director sold 8,000 shares at $81, and on 11/10/2025 sold 2,000 shares at $85. These transactions were made under a Rule 10b5‑1 trading plan dated November 8, 2024. Following the reported trades, the director beneficially owned 15,384 shares.
Globus Medical (GMED) filed a Form 144 notice for a proposed sale of 8,000 common shares, with an aggregate market value of $647,681. The filing lists Raymond James & Associates as broker and indicates an approximate sale date of 11/07/2025 on the NYSE. Company shares outstanding are reported at 133,839,166.
The shares to be sold trace to a stock option exercise on 09/13/2024 for 20,000 shares, paid in cash. The notice also reports a recent transaction: Ann Rhoads sold 10,000 shares on 09/15/2025 for $584,000 in gross proceeds. Form 144 is a notice of intent and does not itself execute a sale; actual sales, if any, follow applicable Rule 144 conditions.
Globus Medical (GMED) reported strong Q3 2025 results. Net sales were $769.0 million versus $625.7 million a year ago, and operating income rose to $137.4 million from $48.1 million. Net income was $119.0 million with diluted EPS of $0.88, up from $0.38. For the first nine months, net sales reached $2.11 billion and net income was $397.3 million, which includes a bargain purchase gain tied to the Nevro transaction.
The company completed the Nevro acquisition on April 3, 2025 for total purchase price of $252.5 million and recorded a bargain purchase gain of $114.4 million year‑to‑date. Musculoskeletal Solutions drove Q3 with $741.0 million in sales, while Enabling Technologies contributed $28.0 million.
Globus ended the quarter with cash and cash equivalents of $371.8 million. Year‑to‑date operating cash flow was $504.9 million. Financing uses included repayment of senior convertible notes of $450.0 million and common stock repurchases of $255.5 million. Inventories were $771.5 million. Shares outstanding were 133,839,166 as of November 3, 2025; this is a baseline figure, not the amount being offered.
Globus Medical (GMED) filed an 8-K stating it issued a press release reporting sales and operating results for the three- and nine-month periods ended September 30, 2025. The press release is included as Exhibit 99.1.
The company notes the information under Item 2.02 and the related exhibit are “furnished” and not “filed” for purposes of Section 18 of the Exchange Act.